Following an analysis of over 12,000 human genes, research from Yale Cancer Center indicated there is cancer-relevant importance in a much larger proportion of human genes than current cancer research models suggest.
Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.
